Moderator of 1 Session
Session Type
Industry Supported Session
Date
10.06.2022
Session Time
16:45 - 17:45
Room
Auditorium 1
Chair(s)
Session Description
The critical role of internal medicine in acute hepatic porphyria
Latest advances to help improve diagnosis and management of this rare disease-Supported by Alnylam
Latest advances to help improve diagnosis and management of this rare disease-Supported by Alnylam
Session Description:
Registration conditions for Givlaari® (givosiran)▼ differ internationally, please refer to your local Prescribing Information for further information.
To report adverse events please refer to your local reporting guidelines.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system of their respective countries.
This symposium will contain information on products developed and marketed by Alnylam Pharmaceuticals.
This symposium is organised and funded by Alnylam Pharmaceuticals, for healthcare professionals only.
AS1-CEMEA-00318 | May 2022
Presenter of 3 Presentations
Panel discussion with live Q&A from the attendees
Session Type
Industry Supported Session
Date
10.06.2022
Session Time
16:45 - 17:45
Room
Auditorium 1
Lecture Time
17:20 - 17:40
Introducing acute hepatic porphyria (AHP) – The current unmet need
Session Type
Industry Supported Session
Date
10.06.2022
Session Time
16:45 - 17:45
Room
Auditorium 1
Presenter
Lecture Time
16:45 - 16:50
Summary and close of the symposium
Session Type
Industry Supported Session
Date
10.06.2022
Session Time
16:45 - 17:45
Room
Auditorium 1
Presenter
Lecture Time
17:40 - 17:45